Previous studies also reported that the effect of first-line treatment with the PD-1 inhibitor pembrolizumab was superior to platinum-doublet chemotherapy in patients with non-small-cell lung cancer and high PD-L1 expression (Aguilar et al., 2019), suggesting that the PD-1 inhibitor pembrolizumab might be an effective therapy for LUAD patients in cluster 2. The gene discussed is CD274; the disease is non-small cell lung carcinoma.